Simplex Trading’s Dyne Therapeutics DYN Stock Holding History

Simplex Trading’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.4K	Sell	1,734 -7,452	-81%	-$129K	﹤0.01%	6333
2025 Q4	$180K	Sell	9,186 -5,652	-38%	-$107K	﹤0.01%	4339
2025 Q3	$187K	Buy	14,838 +1,591	+12%	+$18.1K	﹤0.01%	5014
2025 Q2	$126K	Buy	13,247 +4,452	+51%	+$49K	﹤0.01%	4998
2025 Q1	$91K	Buy	+8,795	New	+$126K	﹤0.01%	5150
2024 Q3	–	Sell	-7,583	Closed	-$302K	–	8731
2024 Q2	$267K	Sell	7,583 -42,123	-85%	-$1.22M	﹤0.01%	4354
2024 Q1	$1.41M	Buy	49,706 +31,645	+175%	+$716K	﹤0.01%	2764
2023 Q4	$240K	Sell	18,061 -17,971	-50%	-$176K	﹤0.01%	4484
2023 Q3	$322K	Buy	+36,032	New	+$388K	﹤0.01%	3860
2022 Q3	–	Sell	-37	Closed	-$424	–	10107
2022 Q2	$0	Buy	+37	New	+$255	﹤0.01%	10171

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Simplex Trading's DYN Position: Q1 2026 in Review

Simplex Trading reduced its Dyne Therapeutics (DYN) stake by 81% in Q1 2026, selling an estimated $129K and leaving 1,734 shares worth $31.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6333.

Simplex Trading first reported a position in DYN in Q2 2022 and has held it in 10 quarters since. The position peaked at $1.41M in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Simplex Trading held 1,734 shares of Dyne Therapeutics worth $31.4K as of Q1 2026.
Simplex Trading sold 7,452 Dyne Therapeutics shares in Q1 2026, an estimated $129K.
Dyne Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6333 holding.
Simplex Trading first reported a position in Dyne Therapeutics in Q2 2022 and has held it in 10 quarters since.
Simplex Trading's Dyne Therapeutics position peaked at $1.41M in Q1 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.